This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response to Modex Therapeutics LLC. The contract is for the development of potent, cross-reactive multispecific antibodies as countermeasures against COVID-19 and seasonal and highly pathogenic avian influenza. The period of performance runs through January 18, 2030. This contract does not have a set-aside designation.
Generated 10/27/24, 2:37 AM